Literature DB >> 8690518

Abundance and state of phosphorylation of the retinoblastoma gene product in human pituitary tumors.

M Woloschak1, A Yu, J Xiao, K D Post.   

Abstract

Targeted disruptions of the retinoblastoma (Rb) gene result in a high frequency of pituitary tumors in heterozygous mice. While our group and others have reported that loss of heterozygosity (LOH) at the Rb locus in human pituitary tumors is rare, these studies have not excluded small inactivating Rb-gene abnormalities more frequently found in human tumors and undetectable by LOH-PCR assays. As a more sensitive means of detecting evidence of these lesions, we have performed Western-blot analysis of several human pituitary tumors to identify Rb loss at the protein level as well as truncated forms of the Rb protein frequently associated with Rb-gene mutations. In 24 tumors, Rb protein was detected at levels 1.4- to 3.9-fold those detected in normal postmortem pituitary. There was no evidence of truncated forms of the Rb protein and only the hypophosphorylated (active) form of the protein was detected in normal and in pituitary tumor specimens. To investigate the possibility of loss of function mutations in certain tumors resulting in the expression of stable, mutant, hypophosphorylated Rb protein, we further performed SSCP analysis of exons 20 through 24 corresponding to the pocket domain of the Rb protein. Of 20 pituitary tumors examined, no mobility shifts could be demonstrated in this analysis. Our findings provide further evidence that primary Rb inactivation is not common in human pituitary tumors. Our detection of only the hypophosphorylated form of the Rb protein probably reflects the low proliferative state of these tumors.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8690518     DOI: 10.1002/(SICI)1097-0215(19960703)67:1<16::AID-IJC4>3.0.CO;2-2

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  13 in total

Review 1.  Genomics and Epigenomics of Pituitary Tumors: What Do Pathologists Need to Know?

Authors:  Sylvia L Asa; Ozgur Mete; Shereen Ezzat
Journal:  Endocr Pathol       Date:  2021-01-12       Impact factor: 3.943

Review 2.  Epidemiology and etiopathogenesis of pituitary adenomas.

Authors:  Elena D Aflorei; Márta Korbonits
Journal:  J Neurooncol       Date:  2014-01-31       Impact factor: 4.130

Review 3.  Genetic basis of pituitary adenoma invasiveness: a review.

Authors:  A Suhardja; K Kovacs; J Rutka
Journal:  J Neurooncol       Date:  2001-05       Impact factor: 4.130

Review 4.  Molecular pathogenesis of acromegaly.

Authors:  M R Drange; S Melmed
Journal:  Pituitary       Date:  1999-06       Impact factor: 4.107

5.  Altered structure and deregulated expression of the tumor suppressor gene retinoblastoma (RB1) in human brain tumors.

Authors:  J Mathivanan; K Rohini; Mohan L Gope; B Anandh; Rajalakshmi Gope
Journal:  Mol Cell Biochem       Date:  2007-02-23       Impact factor: 3.396

Review 6.  Mechanisms for pituitary tumorigenesis: the plastic pituitary.

Authors:  Shlomo Melmed
Journal:  J Clin Invest       Date:  2003-12       Impact factor: 14.808

7.  Epigenetic silencing through DNA and histone methylation of fibroblast growth factor receptor 2 in neoplastic pituitary cells.

Authors:  Xuegong Zhu; Katie Lee; Sylvia L Asa; Shereen Ezzat
Journal:  Am J Pathol       Date:  2007-05       Impact factor: 4.307

8.  Adrenocorticotropin-Producing Pituitary Carcinoma with Expression of c-erbB-2 and High PCNA Index: A Comparative Study with Pituitary Adenomas and Normal Pituitary Tissues.

Authors:  Vania Nose-Alberti; Maria Isabel S. Mesquita; Luciana C. Martin; Marcia J. Kayath
Journal:  Endocr Pathol       Date:  1998       Impact factor: 3.943

Review 9.  Genomic approaches to problems in pituitary neoplasia.

Authors:  Sylvia L Asa; Shereen Ezzat
Journal:  Endocr Pathol       Date:  2014-09       Impact factor: 3.943

Review 10.  Pituitary adenomas: historical perspective, surgical management and future directions.

Authors:  Debebe Theodros; Mira Patel; Jacob Ruzevick; Michael Lim; Chetan Bettegowda
Journal:  CNS Oncol       Date:  2015-10-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.